

Clinical features of respiratory syncytial virus and influenza infections in hospitalized adults across three Italian regions

Tommaso Bigoni,¹ Franco Alfano,¹ Marta Vicentini,² Maria João Fonseca,³ Elisa Turriani,⁴ Elisa Vian,⁵ Micaela Romagnoli,⁶ Massimiliano Beccaria,⁷ Luca Pontalto,¹ Michele Schincaglia,¹ Federico Baraldi,¹ Alberto Papi¹

¹Respiratory Unit, Sant'Anna University Hospital, Ferrara, Italy; ²GlaxoSmithKline, Verona, Italy; ³GlaxoSmithKline, Lisbon, Portugal;

⁴GlaxoSmithKline, Wavre, Belgium; ⁵Microbiology Unit, Cà Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy; ⁶Respiratory Unit, Cà Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy; ⁷Respiratory Unit, ASST Mantua, Italy

Abstract

Acute respiratory infections (ARIs) are important causes of morbidity and mortality globally. Respiratory syncytial virus (RSV) is a highly transmissible viral pathogen that is associated with ARIs, with both RSV and influenza virus infections being leading causes of hospitalization in older (especially frail) individuals. However, prospectively collected data on the incidence of RSV infection are scarce. This prospective study sought to estimate the prevalence of and characterize RSV and influenza virus infection in hospitalized patients. Adult patients (≥ 18 years of age) who were admitted to the respiratory ward of three major hospitals in northern Italy were included in the study and, therefore, had a nasal swab and underwent routine clinical, laboratory, and imaging testing. The primary objective was to estimate the prevalence of influenza virus and RSV infection in these patients.

A total of 246 patients were recruited, 36 of whom had a viral or bacterial respiratory infection. Of these, 9 (3.7% of the total included patients or 25.0% of those with any infection) tested positive for the influenza virus, 5 (55.6%) of whom developed acute respiratory failure, with one dying by 3 months post-discharge. A further 3 patients (1.2% of the total included patients or 8.3% of those with any infection) tested positive for RSV. The three patients with RSV had a greater level of dyspnea and greater severity than those with any infection, and all had pneumonia and developed acute respiratory failure, with one dying during hospitalization.

Influenza and RSV infections were identified in patients hospitalized in respiratory wards in northern Italy. The severe nature of the disease in these patients, including a high rate of pneumonia, emphasizes the importance of preventative measures to protect this vulnerable population and, in particular, vaccination.

Key words: respiratory syncytial virus, influenza virus, respiratory tract infections, hospitalization, comorbidity.

Correspondence to: Alberto Papi, Respiratory Unit, Sant'Anna University Hospital, Ferrara, Italy. Tel.: +39 0532 239752. E-mail: ppa@unife.it

Introduction

Acute respiratory infections (ARIs) are important causes of morbidity and mortality globally. For example, in 2021, ARIs were the fifth leading cause of death globally, and the second cause of death due to a communicable disease (behind COVID-19) [1]. Respiratory syncytial virus (RSV) is a viral pathogen that is associated with ARIs and is highly transmissible, generating clusters of infections, especially over the winter and early spring months [2]. Clinically, older adults, especially those with chronic respiratory or cardiovascular diseases, are at higher risk of severe RSV infection [3,4], and although RSV typically infects the upper respiratory tract, if the lower airways are involved, infection can be associated with pneumonia or exacerbations of asthma or chronic obstructive pulmonary disease (COPD) [5]. Importantly, both RSV and influenza virus infections are leading causes of hospitalization in older (espe-

cially frail) individuals [4,6], emphasizing the importance of RSV and influenza vaccination in this population [7-9].

Despite the availability of sensitive diagnostic techniques for the identification of RSV in biological samples, it is often underdiagnosed, and as a consequence, the impact of RSV infection on hospitalization and mortality may be underestimated. In particular, limited data are available on RSV infection in patients in Italy, although it is known that a high proportion of patients discharged after hospitalization with influenza die after discharge (5.5% in one study, 50% of whom died in the 30 days after discharge) [10]. In addition, limited retrospective data have been published for patients hospitalized with RSV [11,12], and prospectively collected data are scarce; thus, the outcome, clinical presentation, risk factors, and markers (including prognostic) of RSV infection are largely unknown. The study described in this manuscript sought to estimate the prevalence of and to characterize RSV and influenza virus infection in hospitalized patients by using prospective data.



Materials and Methods

This prospective, observational study was conducted in three major hospitals in northern Italy – the University Hospital of Ferrara, the Carlo Poma Hospital in Mantua and the Hospital Ca' Foncello in Treviso. These are hospital hubs for their respective regions, and it is therefore likely that all patients with severe ARIs in these regions would be treated there. Although it had been intended that the study would run between October 2023 and April 2024, delays in ethics committee approval and subsequent study set-up meant that the study was initiated in November 2023 in Ferrara, February 2024 in Mantua, and April 2024 in Treviso.

After obtaining informed consent, all adult patients who were admitted to the respiratory ward during the study period had a nasal swab and underwent routine clinical, laboratory, and imaging testing, including microbiological evaluation of relevant pathogens (bacteria, viruses, and fungi) according to standard procedures at each ward. Molecular RSV and influenza tests were performed on the swabs (Treviso: Allplex™ Respiratory Panel Assays, Seegene Inc, Seoul, South Korea; Ferrara and Montova: Xpert® Xpress Flu/RSV, Cepheid, Sunnyvale, CA, USA). In addition, demographics, clinical presentation at the time of admission [including blood laboratory data, symptoms assessed using a visual analog scale (VAS) and the modified Medical Research Council dyspnea scale (mMRC), and health status using a VAS], and comorbidities (using the Charlson Comorbidity Index) were recorded [13]. Both VAS in the study used a 0-100 scale, with 0 indicating low patient perception of symptoms or low health status burden. Severity at admission was assessed by the National Institute of Allergy and Infectious Disease ordinal scale (NIAID-OS), which ranges from 0 (not hospitalized and with no limitation of activities) to 8 (death).

For analysis purposes, patients were grouped according to the presence of ARI and bacterial or viral infections. The presence of ARI was defined as at least two respiratory symptoms or signs for at least 24 hours or at least one respiratory symptom or sign plus one systemic symptom or sign for at least 24 hours (*Supplementary Material - Methods* for the list of symptoms and signs). In addition, patients were grouped according to the presence of influenza virus or RSV. The non-infected population was defined as hospitalized patients with no microbiological isolation, regardless of whether they were symptomatic or not. The any-infection group included all laboratory-confirmed patients with any pathogen.

To ensure data were representative, the study included all patients ≥ 18 years of age admitted to the respiratory ward of the three hospitals and who provided informed consent, with no other inclusion or exclusion criteria applied. The study was approved by the independent ethics committees at each institution and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice.

Outcomes

The primary objective was to estimate the prevalence of infection with influenza virus and RSV among adults in a respiratory care unit. As secondary objectives, the baseline characteristics were compared between groups according to the presence of ARIs and of bacterial or viral infections, and the baseline characteristics were described in the two groups that tested positive for influenza virus and RSV.

Sample size and statistical methods

The study was not formally powered. Based on available literature, RSV prevalence among patients hospitalized with an ARI was estimated at 4.4%. It was anticipated that between 2200 and 2400 patients would be admitted in total to the three hospitals over the period October 2023 to April 2025, all of whom would agree to take part in the study, and that this would therefore be the total study population. Therefore, the expected number of patients testing positive for RSV would have been 96-106. However, due to delays in ethics committee approval, the study period was severely shortened, which reduced the sample size. For secondary comparisons between groups, continuous data were evaluated using a t-test for normally distributed data and a Wilcoxon test for non-normally distributed data, with categorical data evaluated using a Chi-square test. Statistical tests were performed at a significance level of 0.05. All analyses were performed using STATANow/BE 18.5. All other data (including the primary objective) were analyzed descriptively only.

Results

A total of 246 patients were recruited, the baseline characteristics of whom, stratified by the presence of ARI and infection, are in Table 1. There were a few statistically significant differences in baseline characteristics between these groups of patients. Those with ARI were on average younger than non-ARI individuals ($p=0.003$) and had a lower (*i.e.*, less severe) Charlson Comorbidity Index score ($p<0.001$) and lower eosinophil ($p=0.001$) and lymphocyte ($p=0.003$) counts but were more likely to have radiologically confirmed pneumonia ($p=0.000$) and had a higher (*i.e.*, worse) NIAID-OS score ($p=0.004$; *Supplementary Table 1*). Similarly, compared with patients who did not test positive for any infection, those who tested positive had, on average, a lower Charlson Comorbidity Index score ($p=0.046$) and lower eosinophil ($p<0.001$) and lymphocyte ($p<0.001$) counts, but were more likely to have radiologically confirmed pneumonia ($p=0.000$) and had a higher NIAID-OS score ($p=0.010$). Although the numbers of patients who tested positive for bacterial infections or viral infections were small, therefore limiting the conclusions that can be drawn from these data, compared with patients who did not test positive for any infection, those in these two groups were significantly more likely to have pneumonia ($p=0.000$ and 0.003 for bacterial and viral infections, respectively) and a higher NIAID-OS score ($p=0.009$ and 0.023), with the presence of a viral infection associated with significantly lower eosinophil ($p<0.001$) and lymphocyte ($p<0.001$) counts. There were no differences between groups for any of the other baseline characteristics presented in Table 1. The mean duration of hospitalization was 14.5 (standard deviation 11.8) days in the overall population, compared with 15.4 (13.9), 12.9 (7.7), 13.8 (5.8), and 15.0 (8.8) days in the ARI, any infection, and viral and bacterial infection groups, respectively, with no statistically significant differences between groups.

The presence of ARI signs and symptoms was also compared between the groups. As would be expected, the prevalence was significantly higher in the ARI group than the non-ARI group ($p<0.05$; *Supplementary Table 2*). In addition, compared with patients who did not have a detectable infection, systemic signs or symptoms were more common in patients with any infection ($p=0.021$), and in those with a viral ($p=0.010$) or bacterial ($p=0.023$) infection, with the presence of a viral infection also associated with a greater likelihood of upper respiratory symptoms ($p=0.002$).



Table 1. Baseline characteristics of the recruited patients grouped according to the presence of acute respiratory infection signs or symptoms, and infection.

	No ARI signs or symptoms (n=133)	ARI signs or symptoms (n=113)	Non-infected (n=210)	Patients with an infection		
				Any infection (n=36)	Viral infection (n=12)	Bacterial infection (n=14)
Age, years	69.1 (13.6) (n=132)	64.2 (13.9)	67.3 (13.7)	64.1 (14.9)	58.5 (14.8)	59.8 (16.9)
Sex, male	93 (69.9%)	70 (62.0%)	140 (66.6%)	23 (63.9%)	7 (58.3%)	12 (85.7%)
Smoking history						
Non-smokers	49 (36.8%)	50 (44.3%)	77 (36.8%)	22 (61.1%)	5 (41.7%)	9 (64.3%)
Ex-smokers	53 (39.8%)	35 (31.0%)	84 (40.1%)	9 (25.0%)	2 (16.7%)	2 (14.3%)
Current smokers	31 (23.3%)	26 (23.0%)	48 (22.9%)	4 (11.1%)	4 (33.3%)	3 (21.4%)
Missing	0	2 (1.8%)	0	1 (2.8%)	1 (8.3%)	0
Radiologically confirmed pneumonia	7 (5.3%)	74 (65.5%)	54 (26.2%)	27 (75.0%)	8 (66.7%)	11 (78.6%)
Charlson Comorbidity Index	5.0 (3.1) (n=130)	3.5 (2.4) (n=108)	4.4 (3.0) (n=206)	3.3 (2.4) (n=32)	2.6 (2.0) (n=11)	3.1 (2.8) (n=13)
VAS health status	59.0 (20.9) (n=120)	57.9 (21.1) (n=107)	59.4 (20.4) (n=192)	53.1 (23.2) (n=35)	45.8 (25.4)	58.6 (22.7)
VAS dyspnea	24.7 (31.2) (n=128)	27.7 (31.9) (n=112)	26.6 (31.7) (n=204)	22.7 (30.1)	23.1 (28.3)	34.3 (35.6)
mMRC dyspnea scale	2.1 (1.5) (n=131)	2.3 (1.4) (n=112)	2.2 (1.4) (n=207)	2.2 (1.5)	2.6 (1.2)	2.3 (1.5)
NIAID-OS	4.3 (1.1) (n=129)	4.6 (1.0) (n=112)	4.4 (1.0) (n=205)	4.9 (1.3)	4.9 (1.4)	5.2 (5.2) (1.2)
Total white blood cell count, cells/ μ L	11,689.7 (24,235.2) (n=129)	10,702.2 (11,635.1)	11465.6 (20,862.5)	9871.9 (5600.0)	10,060.0 (4011.5)	9936.4 (3296.9)
Neutrophil count, cells/ μ L	7730.9 (8794.1) (n=128)	8287.6 (8181.1) (n=110)	7998.1 (8978.2) (n=202)	7932.5 (5163.1)	8575.0 (3828.2)	7793.6 (3144.5)
Eosinophil count, cells/ μ L	161.6 (217.5) (n=128)	109.6 (197.2) (n=110)	152.7 (219.6) (n=202)	52.5 (107.6)	7.5 (12.2)	60.7 (81.1)
Lymphocyte count, cells/ μ L	3543.3 (20,448.2) (n=128)	1569.8 (2673.4) (n=110)	2904.8 (16,391.0) (n=202)	1095.8 (537.0)	790.8 (433.4)	1234.3 (593.1)
C-reactive protein, mg/L	18.7 (164.3) (n=113)	69.5 (596.2) (n=102)	5.5 (8.2) (n=184)	14.1 (16.6) (n=31)	17.9 (16.8) (n=11)	17.6 (18.7) (n=12)
Procalcitonin, ng/mL	0.7 (2.9) (n=85)	3.2 (13.2) (n=78)	0.8 (3.3) (n=139)	7.6 (22.8) (n=24)	15.4 (34.2) (n=10)	4.0 (7.0) (n=8)

Categorical variables are presented as numbers (percent), and continuous variables as mean (standard deviation); N values in brackets are the number of patients analyzed when data for a variable are not available for the full population. ARI, acute respiratory infection (see supplement for definition); VAS, visual analog scale; mMRC, modified Medical Research Council; NIAID-OS, National Institute of Allergy and Infectious Disease ordinal scale [ranging from 0 (not hospitalized and with no limitation of activities) to 8 (death)].

Overall, 9 of the 246 patients (3.7%) tested positive for influenza virus (equivalent to 25.0% of the 36 patients with any infection; Table 2). Given these small numbers, the baseline characteristics of these patients were not formally compared between groups. However, patients with influenza appeared to be younger, were more likely to be female and current smokers, and had a numerically lower Charlson Comorbidity Index than the rest of the group with an infection. These patients also had lower eosinophil and lymphocyte counts, with elevated markers of systemic inflammation [*i.e.*, C-reactive protein (C-RP) and procalcitonin]. In this group, 5 patients (55.6%) developed acute respiratory failure, and one had died by 3 months post-discharge. Their mean duration of hospitalization was 14.0 (6.3) days.

A further 3 patients (1.2% of the overall 246 analyzed, or 8.3% of the 36 with any infection) tested positive for RSV. Most of the characteristics of this group were consistent with the rest of the group with an infection – but they had a greater level of dyspnea (both when assessed using the VAS and the mMRC) and a higher (*i.e.*, worse) NIAID-OS score. In addition, these patients had a higher neutrophil count and lower eosinophil and lymphocyte counts, with lower levels of markers of systemic inflammation than the rest of the group with an infection – although the mean values of these systemic markers were still elevated compared with normal values. Of note, all 3 patients had pneumonia and developed acute respiratory failure, and one died during hospitalization. Their mean duration of hospitalization was 13.0 (5.2) days.



Table 2. Baseline characteristics of the recruited patients according to the presence of influenza and respiratory syncytial virus infection.

	Positive for influenza virus (n=9)	Positive for RSV (n=3)
Age, years	56.2 (11.7)	65.3 (23.9)
Sex, male	4 (44.4%)	3 (100%)
Smoking history		
Non-smokers	3 (33.3%)	2 (66.7%)
Ex-smokers	2 (22.2%)	0
Current smokers	4 (44.4%)	0
Missing	0	1 (33.3%)
Radiologically confirmed pneumonia	5 (55.6%)	3 (100%)
Acute respiratory failure	5 (55.6%)	3 (100%)
Died by 3 months post-discharge	1 (11.1%)	1 (33.3%)
Duration of hospitalization (days)	14.0 (6.3)	13.0 (5.2)
Charlson Comorbidity Index	2.3 (1.8) (n=8)	3.7 (2.3)
VAS health status	48.9 (28.0)	36.7 (15.3)
VAS dyspnea	15.6 (22.6)	45.7 (36.7)
mMRC dyspnea scale	2.3 (1.3)	3.3 (0.6)
NIAID-OS	4.7 (1.5)	5.7 (0.6)
Total white blood cell count, cells/ μ L	9546.7 (4214.0)	11,600.0 (3568.2)
Neutrophil count, cells/ μ L	8013.3 (4024.0)	10,260.0 (3186.3)
Eosinophil count, cells/ μ L	8.9 (13.6)	3.3 (5.8)
Lymphocyte count, cells/ μ L	808.9 (388.6)	736.7 (650.4)
C-reactive protein, mg/L	19.8 (19.6) (n=8)	12.9 (2.6)
Procalcitonin, ng/mL	18.6 (38.0) (n=8)	2.7 (3.6) (n=2)

Categorical variables are presented as numbers (percent), and continuous variables as mean (standard deviation); N values in brackets are the number of patients analysed when data for a variable are not available for the full population. RSV, respiratory syncytial virus; VAS, visual analog scale; mMRC, modified Medical Research Council; NIAID-OS, National Institute of Allergy and Infectious Disease ordinal scale [ranging from 0 (not hospitalized and with no limitation of activities) to 8 (death)].

Discussion

The primary objective of this study was to estimate the prevalence of influenza virus and RSV infection among hospitalized adults. Of the 246 patients included in the analyses, 3.7% and 1.2% tested positive for influenza and RSV, respectively – or 25.0% and 8.3%, respectively, of those with any infection. The baseline characteristics of these two groups of patients suggest they are especially complex cases, particularly those who were RSV positive. Both groups of patients had markedly lower eosinophil and lymphocyte counts than the rest of the patients with an infection. Given viral respiratory infections are typically associated with increased sputum eosinophil levels [14,15], the low eosinophil counts in this study are unexpected (indeed 7 of the 12 patients with a viral infection had an eosinophil count of 0 cells/ μ L), but could be due to recruitment of eosinophils into the respiratory system, or may suggest that these patients received oral corticosteroids either prior to or in the emergency room. In addition, acute respiratory failure was common in these patients – with all of those who were RSV positive having both acute respiratory failure and pneumonia. Furthermore, patients who tested positive for RSV had both increased dyspnea and a high NIAID-OS score, again emphasizing the high disease severity in this group of patients. This high disease burden is consistent with an analysis of hospitalized adults aged ≥ 60 years, in which RSV infection was associated with greater odds of pneumonia, intensive care unit admission, COPD exacerbations, and mortality within 1 year post-admission [12].

In the formal comparisons of the baseline characteristics,

although there were few statistically significant differences, patients with ARI symptoms or with a confirmed viral or bacterial infection were at increased risk of radiologically-confirmed pneumonia than those with no ARI symptoms or those with no confirmed infection, suggesting that most patients had been correctly categorized based on clinical examination – although a quarter of the patients who were considered ‘non-infected’ had radiologically-confirmed pneumonia. Of note, the four groups of patients with ARI or a confirmed infection had lower mean eosinophil and lymphocyte counts than the comparator groups (non-ARI and non-infected), and there were no statistically significant differences between groups in either C-RP or procalcitonin concentrations, despite a suggestion from a previous study that raised C-RP levels are indicative of bacterial infection and could be used to guide antibiotic prescribing [16] – although a secondary or concomitant bacterial infection prompted by a primary respiratory virus infection cannot be excluded [14,17]. Taken together, these could suggest that by the time these patients were hospitalized, they had started to recover from the initial infection. This is consistent with the finding that the most common ARI involvement was lower respiratory signs or symptoms (in 92.0% of the ARI group and 91.7–100% of patients with an infection), followed by systemic signs or symptoms (68.1% and 61.1–76.9%, respectively), and with few patients having upper respiratory symptoms (8.8% and 0–23.1%, respectively). However, 83.3% of patients in the ‘non-infected’ group had lower respiratory signs or symptoms (as did 78.2% in the non-ARI group).

The detection of viral and bacterial infections in this study was based on nasal swab results – the current ‘gold standard’. A total of



113 patients met the fairly strict criteria for ARI signs and symptoms, but only 36 tested positive for any infection. This suggests that nasal swabs may not be the best way of excluding the presence of these infections. One option is that patients may have upper respiratory tract infections in the early phase, with that infection then migrating – and most patients are hospitalized only a week or so after the onset of symptoms (by which point it might be too late to identify virus presence in the upper airways). Alternatively, the currently available molecular tests may not be sufficiently sensitive (in a pooled analysis, rapid antigen tests were only 64% sensitive for the detection of RSV) [18]. Of course, this also has an impact on the accuracy of the influenza and RSV prevalence data – patients who were influenza- or RSV-negative according to the nasal swab data may have actually had influenza or RSV infections. Indeed, in an analysis of data from outpatient clinics, of 27 RSV-related exacerbations, 7 were detected only by nasal swab, 16 only by serology, and 4 by both methods [19].

A strength of the study is the ‘real-life’ nature of both the data collected and the patients and physicians involved. The results therefore reflect patients who are actually admitted to a typical specialist respiratory ward in Italy. This also makes the results more difficult to interpret, since rather than recruiting a highly selected population as it is typical of a controlled clinical trial, the population is ‘all comers’, since patients without infections are also admitted to these wards (from lung cancer to exacerbations of lung fibrosis or respiratory failure), and even those patients who do have an infection may also have substantial other underlying diseases (as indicated by the Charlson Comorbidity Index scores). This means that, for example, the dyspnea and health status values reported do not only reflect worsening due to the onset of an infection but are influenced by any underlying disease. Furthermore, the ‘non-infected’ comparator group is, by definition, a group of individuals who have been hospitalized as a consequence of some worsening of a respiratory disease and are therefore not a typical ‘healthy’ control group. This conclusion is supported by the finding that patients with ARI signs or symptoms had a significantly lower Charlson Comorbidity Index score than the non-ARI group.

The main limitation of the study is associated with the delays in initiation – especially at two of the sites, with a substantial reduction in the number of patients actually recruited compared with the planned recruitment. This, in turn, led to a lower number of patients included in the study than originally expected, which reflects the challenges encountered during recruitment. Furthermore, COVID-19 had a significant impact on the incidence of a range of seasonal respiratory virus infections, with a dramatically lower incidence of influenza and RSV during 2020–2021 compared to pre-pandemic seasons [20], and although this study was conducted in the winter of 2023–2024, it is unclear whether the results therefore reflect the ‘real’ epidemiology of these viruses. Ideally, the study should be replicated in subsequent winter seasons, with the presence of RSV identified using both nasal swabs and serology, ideally as early as possible in the course of the infection (rather than on hospitalization).

Conclusions

Influenza and RSV infections were identified in patients hospitalized in respiratory wards in northern Italy. The complex and severe nature of the disease in these patients, including a high rate of pneumonia, emphasizes the importance of preventative measures to

protect this vulnerable population, and in particular vaccination against viral agents. This study thus provides additional support to the recommendations of international and local guidelines [21–23].

References

1. World Health Organization. The top 10 causes of death. 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death>. Accessed on: 28/10/2024.
2. Hababou Y, Taleb A, Recoing A, et al. Molecular investigation of a RSV outbreak in a geriatric hospital. *BMC Geriatr* 2021; 21:120.
3. CDC. Respiratory syncytial virus infection (RSV). RSV in Adults. Available from: <https://www.cdc.gov/rsv/adults/index.html>.
4. Shi T, Vennard S, Jasiewicz F, et al. Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: a systematic review and meta-analysis. *J Infect Dis* 2022;226:S17–21.
5. Lee N, Lui GCY, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. *Clin Infect Dis* 2013;57:1069–77.
6. Tanner AR, Dorey RB, Brendish NJ, Clark TW. Influenza vaccination: protecting the most vulnerable. *Eur Respir Rev* 2021;30:200258.
7. Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. *N Engl J Med* 2023;388:1465–77.
8. Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. *N Engl J Med* 2023;388:595–608.
9. Zeno EE, Nogareda F, Regan A, et al. Interim effectiveness estimates of 2024 Southern Hemisphere influenza vaccines in preventing influenza-associated hospitalization - REVELAC-i Network, Five South American Countries, March–July 2024. *MMWR Morb Mortal Wkly Rep* 2024;73:861–8.
10. O’Halloran AC, Millman AJ, Holstein R, et al. The burden of all-cause mortality following influenza-associated hospitalizations: Influenza Hospitalization Surveillance Network, 2010–2019. *Clin Infect Dis* 2025;80:e43–5.
11. Boattini M, Almeida A, Christaki E, et al. Severity of RSV infection in Southern European elderly patients during two consecutive winter seasons (2017–2018). *J Med Virol* 2021;93:5152–7.
12. Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. *Clin Infect Dis* 2019;69:197–203.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987;40:373–83.
14. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med* 2006;173:1114–21.
15. Zhu J, Mallia P, Footitt J, et al. Bronchial mucosal inflammation and illness severity in response to experimental rhinovirus infection in COPD. *J Allergy Clin Immunol* 2020;146:840–50.e7.
16. Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. *N Engl J Med* 2019;381:111–20.



17. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2012;186:1117-24.
18. Onwuchekwa C, Moreo LM, Menon S, et al. Underascertainment of respiratory syncytial virus infection in adults due to diagnostic testing limitations: a systematic literature review and meta-analysis. *J Infect Dis* 2023;228:173-84.
19. Wiseman DJ, Thwaites RS, Ritchie AI, et al. Respiratory syncytial virus-related community chronic obstructive pulmonary disease exacerbations and novel diagnostics: A binational prospective cohort study. *Am J Respir Crit Care Med* 2024;210:994-1001.
20. Groves HE, Piché-Renaud PP, Peci A, et al. The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study. *Lancet Reg Health Am* 2021;1:100015.
21. Centers for Disease Control and Prevention. RSV vaccine guidance for older adults. 2024. Available from: <https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/older-adults.html>. Accessed on: 4/02/2025.
22. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2025. Available from: <https://goldcopd.org/2025-gold-report/>. Accessed on: 4/02/2025.
23. Global Initiative For Asthma. Global strategy for asthma management and prevention. 2024. Available from: <https://ginasthma.org/2024-report/>. Accessed on: 4/02/2025.

Online supplementary material:

Methods. Definition of acute respiratory infection.

Supplementary Table 1. Statistical comparisons of baseline characteristics.

Supplementary Table 2. Statistical comparisons of acute respiratory infection symptoms.

Received: 5 February 2025; Accepted: 6 March 2025; Early view: 1 April 2025.

Contributions: Tommaso Bigoni, Franco Alfano, Marta Vicentini, Maria João Fonseca, Elisa Turriani, Alberto Papi: study design. Tommaso Bigoni, Franco Alfano, Micaela Romagnoli, Elisa Vian, Massimiliano Beccaria, Luca Pontalto, Michele Schincaglia: data collection. Federico Baraldi: data analysis. All authors revised the manuscript for intellectual content, approved the version to be published, and agreed to be accountable for all aspects of the work.

Conflict of interest: in addition to medical writing support, the authors have the following conflicts of interest to disclose. TB, FA, EV, MR, LP, MS, and FB have no other conflicts to disclose. MV, MJF, and ET are employees of GlaxoSmithKline, and own GlaxoSmithKline stocks. MB declares consulting fees and an honorarium for a presentation from GlaxoSmithKline, all outside the scope of the current manuscript. AP declares payments to his institution from AstraZeneca, Chiesi, GlaxoSmithKline and Sanofi, consulting fees from AstraZeneca, Avillion, Chiesi, GlaxoSmithKline, Moderna, Regeneron, Roche, Sanofi, Zambon, and Zentiva, and payment or honoraria for lectures from AstraZeneca, Avillion, Chiesi, Regeneron, Moderna, GlaxoSmithKline, Roche, Sanofi, and Zambon. All were outside the scope of the current manuscript.

Ethics approval and consent to participate: the study was approved by the independent ethics committees at each institution (Ferrara, Comitato Etico Area Vasta Emilia Centro on 13th September 2023; Mantua, Comitato Etico Territoriale Lombardia 4, on 19th December 2023; Treviso, Comitato Etico Territoriale Area Nord Veneto, on 20th March 2024).

Informed consent: all patients provided informed consent prior to any study-related procedure.

Patient consent for publication: not applicable

Availability of data and materials: the data used to support the findings of this study are available from the corresponding author upon request.

Conference presentation: some of the data in this manuscript were presented at the XXV Congresso Nazionale della Pneumologia SIP/IRS, 2024.

Funding: this study was funded by GlaxoSmithKline (Study ID: 220140).

Acknowledgments: the authors would like to thank the investigators and patients at the investigative sites for their support of this study. Writing support was provided by David Young of Young Medical Communications and Consulting Ltd. This support was funded by Consorzio Futuro in Ricerca, University of Ferrara, Ferrara, Italy.

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

